4.2 Review

Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference

Journal

GEBURTSHILFE UND FRAUENHEILKUNDE
Volume 81, Issue 6, Pages 637-653

Publisher

GEORG THIEME VERLAG KG
DOI: 10.1055/a-1483-2782

Keywords

St; Gallen Consensus 2021; early breast cancer; surgery; radiotherapy; (neo)adjuvant systemic therapy; targeted therapy; St; -Gallen-Konsensus 2021; fruhes Mammakarzinom; Operation; Strahlentherapie; (neo)adjuvante Systemtherapie; zielgerichtete Therapie

Ask authors/readers for more resources

The 17th St. Gallen Consensus Conference on the Treatment of Patients with Early Breast Cancer focused on customizing local and systemic therapies for women with early breast cancer, emphasizing the challenge of individualized treatment. A German working group of leading breast cancer experts discussed the international conference results and compared them with the German guidelines to incorporate country-specific aspects. Both the German treatment recommendations of the AGO and the S3 guideline are evidence-based, but therapeutic decisions should always be based on a risk-benefit analysis for each specific situation and discussed with the patient.
This years 17th St. Gallen (SG) Consensus Conference on the Treatment of Patients with Early Breast Cancer (SG-BCC) with the title Customizing local and systemic therapies for women with early breast cancer focused on the challenge of targeting the treatment of early breast cancer more specifically to the individual disease situation of each patient. As in previous years, a German working group of leading breast cancer experts discussed the results of the international SG-BCC 2021 in the context of the German guideline. It is helpful to compare the SG recommendations with the recently updated treatment recommendations of the Breast Commission of the German Working Group on Gynaecological Oncology (Arbeitsgemeinschaft Gynakologische Onkologie e.V., AGO) and the S3 guideline because the SG-BCC panel comprised experts from different countries, which is why country-specific aspects can be incorporated into the SG recommendations. The German treatment recommendations of the AGO and the S3 guideline are based on current evidence. Nevertheless, any therapeutic decision must always undergo a risk-benefit analysis for the specific situation and to be discussed with the patient. Zusammenfassung Die diesjahrige 17. St.-Gallen-(SG-)Konsensus-Konferenz zur Behandlung von Patientinnen mit fruhem Mammakarzinom (SG-BCC) stand unter dem Motto Customizing local and systemic therapies for women with early breast cancer und fokussierte auf die Herausforderung, die Behandlung des fruhen Mammakarzinoms zielgerichteter auf die individuelle Krankheitssituation adaptieren. Wie schon in den vergangenen Jahren hat auch dieses Jahr eine deutsche Arbeitsgruppe fuhrender Brustkrebsexpert*Innen die Ergebnisse der internationalen SG-BCC 2021 vor dem Hintergrund der deutschen Therapieempfehlungen fur den Klinikalltag in Deutschland diskutiert. Der Vergleich der SG-Empfehlungen mit den erst kurzlich aktualisierten Therapieempfehlungen der Kommission Mamma der Arbeitsgemeinschaft Gynakologische Onkologie e.V. (AGO) sowie der S3-Leitlinie ist hilfreich, da sich das SG-BCC-Panel aus Experten unterschiedlicher Lander zusammensetzt, weshalb landerspezifische Besonderheiten in die SG-Empfehlungen einflie ss en konnen. Die deutschen Therapieempfehlungen der AGO sowie der S3-Leitlinie basieren auf der aktuellen Evidenz. Gleichwohl muss jede Therapieentscheidung immer einer Nutzen-Risiko-Abwagung fur die individuelle Situation unterzogen und mit der Patientin besprochen werden.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available